within Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J02A_AntimycoticsForSystemicUse.J02AC03_Voriconazole;

model Voriconazole
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C_enteral(
    weight = 70,
    F = 0.96,
    Cl = 1.6666666666666667e-06,
    adminDuration = 600,
    adminMass = 200 / 1000000,
    adminCount = 1,
    Vd = 0.0046,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.00065,
    Tlag = 780,
    Vdp = 0.0052,
    k12 = 0.0001186111111111111,
    k21 = 0.0001186111111111111);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Voriconazole</td></tr><tr><td>ATC code:</td><td>J02AC03</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>200</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>4.6</td><td>L</td></tr>
    <tr><td>clearance:</td><td>6</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Voriconazole is a triazole antifungal medication approved for the treatment of invasive aspergillosis and serious infections caused by other yeasts and fungi, such as Candida species. It is used in immunocompromised patients, including those with hematopoietic stem cell transplants or advanced HIV infection, and remains widely approved and in clinical use today.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics reported in healthy adult volunteers, both male and female, after a single oral dose under fasting conditions.</p><h4>References</h4><ol><li><p>Chen, N, et al., &amp; Lu, X (2023). Population Pharmacokinetics of Isavuconazole in Adult: A Systematic Review. <i>Infection and drug resistance</i> 16 7559–7568. DOI:<a href=\"https://doi.org/10.2147/IDR.S434622\">10.2147/IDR.S434622</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/38089964/\">https://pubmed.ncbi.nlm.nih.gov/38089964</a></p></li><li><p>Hope, WW (2012). Population pharmacokinetics of voriconazole in adults. <i>Antimicrobial agents and chemotherapy</i> 56(1) 526–531. DOI:<a href=\"https://doi.org/10.1128/AAC.00702-11\">10.1128/AAC.00702-11</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/22064545/\">https://pubmed.ncbi.nlm.nih.gov/22064545</a></p></li><li><p>Tang, D, et al., &amp; Xiang, DX (2021). Population pharmacokinetics, safety and dosing optimization of voriconazole in patients with liver dysfunction: A prospective observational study. <i>British journal of clinical pharmacology</i> 87(4) 1890–1902. DOI:<a href=\"https://doi.org/10.1111/bcp.14578\">10.1111/bcp.14578</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33010043/\">https://pubmed.ncbi.nlm.nih.gov/33010043</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.J.J02AC03 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Voriconazole;
